(Q36149549)

12 August 2017

Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia (English)

1 reference

12 August 2017

0 references

0 references

1 reference

Georg Aue

1

1 reference

12 August 2017

Jay Nelson Lozier

2

1 reference

12 August 2017

Xin Tian

3

1 reference

12 August 2017

Ann M Cullinane

4

1 reference

12 August 2017

Susan Soto

5

1 reference

12 August 2017

Leigh Samsel

6

1 reference

12 August 2017

Philip McCoy

7

1 reference

12 August 2017

Adrian Wiestner

8

1 reference

12 August 2017

2 August 2011

1 reference

American Journal of Hematology

12 August 2017

1 reference

12 August 2017

86

1 reference

12 August 2017

10

1 reference

12 August 2017

835-840

1 reference

Immunomodulatory drugs increase endothelial tissue factor expression in vitro

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Role of TNF-alpha in vascular dysfunction

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Hemostatic complications of angiogenesis inhibitors in cancer patients.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Lenalidomide for the treatment of B-cell malignancies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Aspirin, TNF-alpha, NFkB, and survival in multiple myeloma: the importance of measuring TNF-alpha

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Tumor necrosis factor: an apoptosis JuNKie?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

2 July 2018

1 reference

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

21 January 2018

1 reference

Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.

21 January 2018

1 reference

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

21 January 2018

1 reference

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3414537

Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis

23 September 2018

1 reference

The relationship between inflammation and venous thrombosis. A systematic review of clinical studies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21812019

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21812019

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/AJH.22114

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

21812019

1 reference